10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting

PLEASANTON, Calif., Oct. 1, 2024 /PRNewswire/ — At the Human Cell Atlas General Meeting held September 29-30 in Milan, Italy, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, shared new details about its upcoming product roadmap and its ongoing strategy to democratize access to single cell analysis.

During its Foundational Sponsor talk in the Sept. 29 Technology Showcase, 10x Genomics announced an imminent plan to deliver “single cell for a single cent.” Through a series of new products and configurations expected to launch this quarter, 10x Genomics intends to deliver mega-scale single cell analysis at a cost as low as $0.01 per cell. 10x Genomics believes its upcoming launches, which enable 2.5 million cells per run and 5 million cells per kit, will be the most cost effective single cell products available for CRISPR screens, cell atlassing projects and other high-throughput applications.

“We know price is an important consideration, both for new researchers embarking on their first single cell experiment and current customers looking to do more – whether that’s analyzing more cells or more samples, or running more experiments, more routinely,” said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. “By continuing to deliver single cell technologies that offer superior performance and superior economics, we believe we can expand the single cell opportunity, drive widespread adoption and make single cell analysis the standard for most biological research.”

In addition to new solutions for mega-scale applications, 10x Genomics’ planned launches this quarter will feature cost effective products to increase access to and adoption of single cell in additional applications and use cases. These new offerings are expected to enable researchers to perform single cell experiments, even at a small scale, for approximately $560 per sample.

As part of the company’s strategy to democratize access to single cell analysis, 10x Genomics introduced several new products earlier this year to drive down customer cost in multiple directions: per cell, per sample, per experiment and per project. This includes:

Chromium GEM-X Technology: In March, 10x Genomics launched the first two products on its new GEM-X technology architecture, which enables increased sensitivity and capture efficiency, improved robustness and scalability and a more than two-fold reduction in cost per cell.
Chromium Xo: Last month, 10x Genomics announced the launch of Chromium Xo, the company’s most affordable single cell instrument. Chromium Xo delivers the high-quality data, superior reproducibility and ease of use that the company’s instrument-powered workflows are known for, at a U.S. list price of $25,000.

“For nearly a decade, researchers have known 10x as the single cell technology leader,” added Schnall-Levin. “Our upcoming launches will reinforce Chromium’s leadership in both high performance and low cost, because researchers should never have to compromise one for the other. We can’t wait to show the world what we’ve been working on.”

About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the “safe harbor” provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “see,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding 10x Genomics, Inc.’s (“10x Genomics”) and others’ product launches, performance, configuration, costs, capabilities, requirements, workflows, applications, adoption, opportunities, leadership and pipeline. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics’ financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the “SEC”) from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics’ views as of any date subsequent to the date of this press release.

Disclosure Information10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

ContactsInvestors: [email protected]Media: [email protected]

SOURCE 10x Genomics, Inc.